Any pause in taking the osteoporosis drug risedronate (Actonel) should last no longer than 2 years rather than the 2 to 3 years currently recommended for bisphosphonates, new research suggests.
In a cohort...
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok